| Symbol | VRTX |
|---|---|
| Name | VERTEX PHARMACEUTICALS INC / MA |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 50 NORTHERN AVENUE, BOSTON, MA 02210 |
| Telephone | 6173416393 |
| Fax | — |
| — | |
| Website | https://www.vrtx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000875320 |
| Description | Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. Additional info from NASDAQ: |
2026-08-03 20:09
(30% Negative) VERTEX PHARMACEUTICALS INC / MA (VRTX) Announces Business Combination
Read more
2026-07-23 20:15
Tatsis Ourania 🟢 acquired 8.3K shares of VERTEX PHARMACEUTICALS INC / MA (VRTX) Transaction Date: Jul 21, 2026 | Filing ID: 000253
Read more
2026-07-23 20:13
Sachdev Amit 🟢 acquired 8.3K shares of VERTEX PHARMACEUTICALS INC / MA (VRTX) Transaction Date: Jul 21, 2026 | Filing ID: 000251
Read more
2026-07-17 20:06
Director SACHS BRUCE I 🟢 acquired 100 shares (1 derivative) of VERTEX PHARMACEUTICALS INC / MA (VRTX) Transaction Date: Jul 15, 2026 | Filing ID: 000249
Read more
2026-07-17 20:05
Director Garber Alan M 🟢 acquired 32 shares (1 derivative) of VERTEX PHARMACEUTICALS INC / MA (VRTX) Transaction Date: Jul 15, 2026 | Filing ID: 000247
Read more
2026-07-07 20:15
Tatsis Ourania 🔴 sold 1.5K shares of VERTEX PHARMACEUTICALS INC / MA (VRTX) at $524.99 Transaction Date: Jul 02, 2026 | Filing ID: 000245
Read more
2026-07-07 20:08
McKechnie Duncan 🔴 sold 1.5K shares of VERTEX PHARMACEUTICALS INC / MA (VRTX) at $519.00 Transaction Date: Jul 02, 2026 | Filing ID: 000243
Read more
2026-07-06 20:13
Liu Joy 🔴 sold 828 shares of VERTEX PHARMACEUTICALS INC / MA (VRTX) at $502.71 Transaction Date: Jul 01, 2026 | Filing ID: 000241
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04058210 | VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Hetero… | — | Cystic Fibrosis | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT03278314 | Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 1… | — | Cystic Fibrosis | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT01381289 | VX-770 Expanded Access Program | — | Cystic Fibrosis | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT04702360 | ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at L… | — | Cystic Fibrosis | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT05951205 | Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants W… | Phase3 | Sickle Cell Disease | Withdrawn | 2027-07-31 | 2033-12-31 | ClinicalTrials.gov |
| NCT07700225 | Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (EN… | — | DM1 | Recruiting | 2026-08-01 | 2032-12-01 | ClinicalTrials.gov |
| NCT07654296 | Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery | Phase3 | Opioid Consumption, Postoperative | Not_Yet_Recruiting | 2026-08-01 | 2027-03-31 | ClinicalTrials.gov |
| NCT07624526 | Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid… | Phase4 | Knee Arthritis | Not_Yet_Recruiting | 2026-07-01 | 2028-08-01 | ClinicalTrials.gov |
| NCT07584434 | A Phase 1, First-in-human Study of VX-433 | Phase1 | Narcolepsy Type 1 (NT1) | Recruiting | 2026-05-21 | 2027-03-05 | ClinicalTrials.gov |
| NCT07501702 | A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia … | Phase2 | Myasthenia Gravis, Generalized | Recruiting | 2026-05-13 | 2029-03-02 | ClinicalTrials.gov |
| NCT07570069 | Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Particip… | Phase1 | Pain | Completed | 2026-05-07 | 2026-07-16 | ClinicalTrials.gov |
| NCT07538570 | Evaluation of Pain Treatment After Total Knee Arthroplasty | Phase4 | Pain | Recruiting | 2026-04-24 | 2027-01-30 | ClinicalTrials.gov |
| NCT07463430 | Suzetrigine for Non-Mastectomy Breast Surgery | Phase4 | Pain, Acute Postoperative | Enrolling_By_Invitation | 2026-04-14 | 2027-12-31 | ClinicalTrials.gov |
| NCT07437105 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in H… | Phase1 | Cystic Fibrosis | Recruiting | 2026-02-25 | 2027-03-23 | ClinicalTrials.gov |
| NCT07378865 | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactatin… | Phase1 | Pain | Recruiting | 2026-02-13 | 2027-02-26 | ClinicalTrials.gov |
| NCT07349394 | Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Ros… | Phase1 | Cystic Fibrosis | Completed | 2026-01-12 | 2026-03-12 | ClinicalTrials.gov |
| NCT07283770 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in H… | Phase1 | Cystic Fibrosis | Recruiting | 2025-12-09 | 2026-11-19 | ClinicalTrials.gov |
| NCT07231419 | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With… | Phase3 | Diabetic Peripheral Neuropathic Pain | Recruiting | 2025-11-21 | 2027-04-06 | ClinicalTrials.gov |
| NCT07161037 | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 G… | Phase2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Active_Not_Recruiting | 2025-11-19 | 2027-12-31 | ClinicalTrials.gov |
| NCT07204275 | Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participant… | Phase2 | Primary Membranous Nephropathy | Recruiting | 2025-09-30 | 2028-12-29 | ClinicalTrials.gov |
| NCT07074327 | Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Par… | Phase1 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Completed | 2025-07-11 | 2026-02-27 | ClinicalTrials.gov |
| NCT07022119 | A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407… | Phase1 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Completed | 2025-06-12 | 2026-02-24 | ClinicalTrials.gov |
| NCT07010406 | A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations a… | Phase1 | Healthy Volunteers | Completed | 2025-06-06 | 2025-08-19 | ClinicalTrials.gov |
| NCT06926621 | A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotoni… | Phase2 | Myotonic Dystrophy Type 1 (DM1) | Enrolling_By_Invitation | 2025-04-28 | 2029-01-30 | ClinicalTrials.gov |
| NCT06861413 | A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet For… | Phase1 | Cystic Fibrosis | Completed | 2025-04-01 | 2025-05-05 | ClinicalTrials.gov |
| NCT06832410 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type… | Phase3 | Type 1 Diabetes | Recruiting | 2025-03-31 | 2027-09-17 | ClinicalTrials.gov |
| NCT06887959 | A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ)… | Phase4 | Acute Pain | Completed | 2025-03-27 | 2025-11-10 | ClinicalTrials.gov |
| NCT06886269 | A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose | Phase1 | Pain | Completed | 2025-03-21 | 2025-05-17 | ClinicalTrials.gov |
| NCT06887972 | A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ)… | Phase4 | Acute Pain | Completed | 2025-03-21 | 2025-11-07 | ClinicalTrials.gov |
| NCT06834009 | A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Pane… | Phase1 | Pain | Completed | 2025-03-10 | 2025-04-24 | ClinicalTrials.gov |
| NCT06820307 | Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral C… | Phase1 | Pain | Completed | 2025-02-25 | 2025-04-29 | ClinicalTrials.gov |
| NCT06794996 | Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With o… | Phase2 | Proteinuric Kidney Disease | Active_Not_Recruiting | 2025-02-04 | 2026-12-30 | ClinicalTrials.gov |
| NCT06747572 | Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Po… | — | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Active_Not_Recruiting | 2024-12-19 | 2026-12-31 | ClinicalTrials.gov |
| NCT06696443 | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Pa… | Phase3 | Diabetic Peripheral Neuropathic Pain | Active_Not_Recruiting | 2024-12-18 | 2027-01-25 | ClinicalTrials.gov |
| NCT06460506 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis P… | Phase3 | Cystic Fibrosis | Active_Not_Recruiting | 2024-11-21 | 2027-09-30 | ClinicalTrials.gov |
| NCT06619847 | A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunione… | Phase2 | Acute Pain | Completed | 2024-10-29 | 2025-05-27 | ClinicalTrials.gov |
| NCT06619860 | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic P… | Phase2 | Diabetic Peripheral Neuropathic Pain | Recruiting | 2024-10-18 | 2027-04-22 | ClinicalTrials.gov |
| NCT06628908 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabe… | Phase3 | Diabetic Peripheral Neuropathic Pain | Recruiting | 2024-10-01 | 2027-05-31 | ClinicalTrials.gov |
| NCT06615570 | A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants | Phase1 | Pain | Completed | 2024-09-30 | 2025-07-21 | ClinicalTrials.gov |
| NCT06147778 | Performances and Safety of MuCopilot, a Digital Tool for the Unsupervised Objec… | Na | Cystic Fibrosis | Completed | 2024-09-18 | 2025-09-24 | ClinicalTrials.gov |
| NCT06529796 | Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With… | Phase1 | Focal Segmental Glomerulosclerosis (FSGS) | Completed | 2024-08-02 | 2024-12-20 | ClinicalTrials.gov |
| NCT06523595 | Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Met… | Phase1 | Pain | Completed | 2024-07-31 | 2024-12-31 | ClinicalTrials.gov |
| NCT06508762 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Table… | Phase1 | Pain | Completed | 2024-07-26 | 2024-09-10 | ClinicalTrials.gov |
| NCT06506773 | Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fi… | — | Cystic Fibrosis | Completed | 2024-07-09 | 2025-11-27 | ClinicalTrials.gov |
| NCT06420765 | A Microneurography Study of NaV1.8 Inhibition in Healthy Adults | Phase1 | Pain | Completed | 2024-05-21 | 2025-04-04 | ClinicalTrials.gov |
| NCT06394167 | A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults | Phase1 | Pain | Completed | 2024-05-09 | 2025-02-18 | ClinicalTrials.gov |
| NCT06392659 | A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Inter… | Phase1 | Pain | Completed | 2024-05-02 | 2024-07-02 | ClinicalTrials.gov |
| NCT06345755 | A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-40… | Phase1 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Completed | 2024-04-17 | 2025-06-13 | ClinicalTrials.gov |
| NCT06312787 | A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Ta… | Phase1 | Cystic Fibrosis | Completed | 2024-04-02 | 2024-05-04 | ClinicalTrials.gov |
| NCT06336096 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Table… | Phase1 | Pain | Completed | 2024-03-28 | 2024-06-19 | ClinicalTrials.gov |
| NCT06299696 | A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adul… | Phase1 | Cystic Fibrosis | Completed | 2024-03-26 | 2024-04-16 | ClinicalTrials.gov |
| NCT06299709 | A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proport… | Phase1 | Cystic Fibrosis | Completed | 2024-03-13 | 2024-05-23 | ClinicalTrials.gov |
| NCT06185764 | A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM… | Phase1 | Myotonic Dystrophy Type 1 (DM1) | Recruiting | 2024-02-20 | 2027-02-02 | ClinicalTrials.gov |
| NCT06226454 | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, … | Phase1 | Pain | Completed | 2024-01-04 | 2024-06-12 | ClinicalTrials.gov |
| NCT06176196 | Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopat… | Phase2 | Painful Lumbosacral Radiculopathy | Completed | 2023-12-13 | 2024-10-16 | ClinicalTrials.gov |
| NCT06154447 | Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fi… | Phase1 | Cystic Fibrosis | Completed | 2023-12-12 | 2026-07-10 | ClinicalTrials.gov |
| NCT05844449 | Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivaca… | Phase3 | Cystic Fibrosis | Enrolling_By_Invitation | 2023-08-11 | 2029-07-30 | ClinicalTrials.gov |
| NCT05955872 | A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet For… | Phase1 | Focal Segmental Glomerulosclerosis (FSGS) | Completed | 2023-07-19 | 2023-09-02 | ClinicalTrials.gov |
| NCT05882357 | Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis… | Phase3 | Cystic Fibrosis | Completed | 2023-06-27 | 2025-09-04 | ClinicalTrials.gov |
| NCT05865171 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participan… | Phase1 | Renal Impairment | Completed | 2023-06-12 | 2024-06-12 | ClinicalTrials.gov |
| NCT05791201 | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type … | Phase1 | Type 1 Diabetes | Active_Not_Recruiting | 2023-05-16 | 2027-03-12 | ClinicalTrials.gov |
| NCT05866055 | A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults | Phase1 | Pain | Completed | 2023-05-10 | 2024-04-04 | ClinicalTrials.gov |
| NCT05851157 | A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548 | Phase1 | Pain | Completed | 2023-05-03 | 2023-11-08 | ClinicalTrials.gov |
| NCT05867147 | An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc … | Phase1 | Cystic Fibrosis | Completed | 2023-04-26 | 2023-06-14 | ClinicalTrials.gov |
| NCT05818852 | A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Part… | Phase1 | Pain | Completed | 2023-04-12 | 2023-06-28 | ClinicalTrials.gov |
| NCT05668741 | A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) | Phase1 | Cystic Fibrosis | Active_Not_Recruiting | 2023-02-27 | 2026-09-09 | ClinicalTrials.gov |
| NCT05704556 | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Re… | Phase1 | Pain | Completed | 2023-02-27 | 2024-03-30 | ClinicalTrials.gov |
| NCT05643495 | A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ… | Phase2 | Alpha-1 Antitrypsin Deficiency | Terminated | 2023-02-23 | 2024-08-19 | ClinicalTrials.gov |
| NCT05727800 | A Phase 1, First-in-human Study of VX-668 | Phase1 | Alpha-1 Antitrypsin Deficiency | Completed | 2023-02-08 | 2024-02-13 | ClinicalTrials.gov |
| NCT05661734 | A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain | Phase3 | Pain | Completed | 2023-01-09 | 2023-12-12 | ClinicalTrials.gov |
| NCT05660538 | Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neu… | Phase2 | Diabetic Peripheral Neuropathy | Completed | 2022-12-20 | 2023-10-25 | ClinicalTrials.gov |
| NCT05635110 | Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of… | Phase1 | Pain | Completed | 2022-12-15 | 2023-06-08 | ClinicalTrials.gov |
| NCT05653323 | A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants | Phase1 | Pain | Completed | 2022-12-14 | 2023-09-12 | ClinicalTrials.gov |
| NCT05331183 | Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safe… | Phase3 | Cystic Fibrosis | Active_Not_Recruiting | 2022-11-23 | 2027-04-06 | ClinicalTrials.gov |
| NCT05444257 | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Ther… | Phase3 | Cystic Fibrosis | Active_Not_Recruiting | 2022-11-08 | 2026-10-30 | ClinicalTrials.gov |
| NCT05560464 | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mi… | Phase1 | Pain | Completed | 2022-10-14 | 2023-07-24 | ClinicalTrials.gov |
| NCT05579431 | A Phase 1, First-in-human Study of VX-634 | Phase1 | Alpha 1-Antitrypsin Deficiency | Completed | 2022-10-13 | 2023-11-13 | ClinicalTrials.gov |
| NCT05558410 | Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdomi… | Phase3 | Acute Pain | Completed | 2022-10-10 | 2023-09-11 | ClinicalTrials.gov |
| NCT05553366 | Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | Phase3 | Acute Pain | Completed | 2022-10-03 | 2023-12-15 | ClinicalTrials.gov |
| NCT05541471 | A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, … | Phase1 | Pain | Completed | 2022-09-22 | 2023-04-28 | ClinicalTrials.gov |
| NCT05518734 | A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants | Phase1 | Pain | Completed | 2022-09-17 | 2023-03-07 | ClinicalTrials.gov |
| NCT05535959 | A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Ta… | Phase1 | Cystic Fibrosis | Completed | 2022-09-15 | 2022-11-09 | ClinicalTrials.gov |
| NCT05477563 | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants Wi… | Phase3 | Beta-Thalassemia | Recruiting | 2022-08-02 | 2027-06-09 | ClinicalTrials.gov |
| NCT05437120 | Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Pa… | Phase1 | Cystic Fibrosis | Completed | 2022-07-22 | 2023-03-16 | ClinicalTrials.gov |
| NCT05455502 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Table… | Phase1 | Pain | Completed | 2022-07-13 | 2022-09-17 | ClinicalTrials.gov |
| NCT05422222 | Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participa… | Phase3 | Cystic Fibrosis | Active_Not_Recruiting | 2022-06-21 | 2030-06-30 | ClinicalTrials.gov |
| NCT05418712 | A Microneurography (MNG) Study of VX-150 in Healthy Participants | Phase1 | Pain | Completed | 2022-06-16 | 2022-09-23 | ClinicalTrials.gov |
| NCT05274269 | Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/… | Phase3 | Cystic Fibrosis | Completed | 2022-05-09 | 2023-07-05 | ClinicalTrials.gov |
| NCT05356195 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Tran… | Phase3 | Beta-Thalassemia | Active_Not_Recruiting | 2022-05-03 | 2027-11-14 | ClinicalTrials.gov |
| NCT05329649 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Seve… | Phase3 | Sickle Cell Disease | Active_Not_Recruiting | 2022-05-02 | 2027-06-06 | ClinicalTrials.gov |
| NCT05347394 | A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants | Phase1 | Acute Pain | Completed | 2022-04-08 | 2023-04-14 | ClinicalTrials.gov |
| NCT05324410 | A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of… | Phase1 | APOL1-mediated Kidney Disease | Completed | 2022-04-07 | 2022-11-07 | ClinicalTrials.gov |
| NCT05312879 | Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APO… | Phase2 | Proteinuric Kidney Disease | Recruiting | 2022-03-30 | 2030-05-07 | ClinicalTrials.gov |
| NCT05153317 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (… | Phase3 | Cystic Fibrosis | Completed | 2022-01-17 | 2026-01-29 | ClinicalTrials.gov |
| NCT05111145 | A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participan… | Phase3 | Cystic Fibrosis | Completed | 2022-01-14 | 2022-12-20 | ClinicalTrials.gov |
| NCT04066751 | The Multicenter Topic Trial | Phase2 | Chronic Obstructive Pulmonary Disease | Withdrawn | 2021-12-01 | 2024-10-31 | ClinicalTrials.gov |
| NCT05076149 | A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF)… | Phase3 | Cystic Fibrosis | Completed | 2021-10-27 | 2023-11-30 | ClinicalTrials.gov |
| NCT04969224 | A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants … | Phase3 | Cystic Fibrosis | Completed | 2021-10-12 | 2022-07-26 | ClinicalTrials.gov |
| NCT05033080 | A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibro… | Phase3 | Cystic Fibrosis | Completed | 2021-09-14 | 2023-11-21 | ClinicalTrials.gov |
| NCT05034952 | A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdomi… | Phase2 | Acute Pain | Completed | 2021-08-30 | 2021-12-21 | ClinicalTrials.gov |
| NCT04977336 | A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunione… | Phase2 | Acute Pain | Completed | 2021-07-19 | 2022-03-04 | ClinicalTrials.gov |
| NCT04923464 | A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using W… | — | Cystic Fibrosis | Completed | 2021-06-30 | 2021-12-20 | ClinicalTrials.gov |
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type … | Phase3 | Diabetes Mellitus, Type 1 | Recruiting | 2021-03-29 | 2030-06-30 | ClinicalTrials.gov |
| NCT04208529 | A Long-term Follow-up Study in Participants Who Received CTX001 | Phase3 | Beta-Thalassemia | Enrolling_By_Invitation | 2021-01-20 | 2039-09-30 | ClinicalTrials.gov |
| NCT04599465 | A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participant… | Phase3 | Cystic Fibrosis | Completed | 2021-01-15 | 2022-07-14 | ClinicalTrials.gov |
| NCT04545515 | A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/… | Phase3 | Cystic Fibrosis | Completed | 2021-01-11 | 2023-03-24 | ClinicalTrials.gov |
| NCT04537793 | Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years | Phase3 | Cystic Fibrosis | Completed | 2020-11-19 | 2022-06-03 | ClinicalTrials.gov |
| NCT04618185 | Gut Imaging for Function & Transit in CF - GIFT-CF 3 | — | Cystic Fibrosis | Completed | 2020-10-21 | 2023-06-28 | ClinicalTrials.gov |
| NCT04474197 | Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genot… | Phase2 | Alpha1-Antitrypsin Deficiency | Completed | 2020-07-24 | 2021-05-04 | ClinicalTrials.gov |
| NCT04353817 | A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in S… | Phase3 | Cystic Fibrosis | Completed | 2020-06-19 | 2021-05-17 | ClinicalTrials.gov |
| NCT04340362 | Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerul… | Phase2 | Glomerulosclerosis, Focal Segmental | Completed | 2020-06-08 | 2021-12-09 | ClinicalTrials.gov |
| NCT04362761 | A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy | Phase3 | Cystic Fibrosis | Completed | 2020-05-04 | 2022-12-21 | ClinicalTrials.gov |
| NCT04254705 | Organoid Study R334W | Na | Cystic Fibrosis | Withdrawn | 2020-03-01 | 2021-03-01 | ClinicalTrials.gov |
| NCT04235140 | Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis W… | Phase3 | Cystic Fibrosis | Completed | 2020-02-24 | 2023-08-22 | ClinicalTrials.gov |
| NCT04183790 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Thera… | Phase3 | Cystic Fibrosis | Completed | 2020-02-17 | 2024-02-24 | ClinicalTrials.gov |
| NCT04167345 | Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genot… | Phase2 | Alpha 1-Antitrypsin Deficiency | Terminated | 2020-01-13 | 2020-11-14 | ClinicalTrials.gov |
| NCT04058366 | Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | Phase3 | Cystic Fibrosis | Completed | 2019-12-05 | 2022-12-16 | ClinicalTrials.gov |
| NCT04105972 | A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cy… | Phase3 | Cystic Fibrosis | Completed | 2019-10-03 | 2020-07-24 | ClinicalTrials.gov |
| NCT04006873 | Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 | Phase2 | Cystic Fibrosis | Completed | 2019-09-03 | 2020-10-29 | ClinicalTrials.gov |
| NCT04058353 | A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects … | Phase3 | Cystic Fibrosis | Completed | 2019-08-28 | 2020-06-12 | ClinicalTrials.gov |
| NCT04043806 | A Study Evaluating the Long-term Safety of VX-445 Combination Therapy | Phase3 | Cystic Fibrosis | Completed | 2019-08-09 | 2022-12-14 | ClinicalTrials.gov |
| NCT03912233 | A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Su… | Phase2 | Cystic Fibrosis | Completed | 2019-04-30 | 2019-12-10 | ClinicalTrials.gov |
| NCT03911713 | A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Y… | Phase2 | Cystic Fibrosis | Completed | 2019-04-17 | 2020-08-20 | ClinicalTrials.gov |
| NCT03795363 | Orkambi Treatment in 2 to 5 Year Old Children With CF | — | Cystic Fibrosis | Completed | 2019-04-10 | 2021-06-16 | ClinicalTrials.gov |
| NCT03859531 | Gastrointestinal Study at Orkambi Therapy in CF Patients | — | Cystic Fibrosis | Unknown | 2019-02-27 | 2020-06-30 | ClinicalTrials.gov |
| NCT03783286 | Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects | — | Cystic Fibrosis | Completed | 2019-02-06 | 2021-12-30 | ClinicalTrials.gov |
| NCT03764072 | A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With… | Phase2 | Acute Pain | Completed | 2018-12-12 | 2019-01-25 | ClinicalTrials.gov |
| NCT03745287 | A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Ce… | Phase2 | Sickle Cell Disease | Completed | 2018-11-27 | 2025-07-07 | ClinicalTrials.gov |
| NCT03525574 | A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Ther… | Phase3 | Cystic Fibrosis | Completed | 2018-10-09 | 2023-01-09 | ClinicalTrials.gov |
| NCT03691779 | Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of … | Phase3 | Cystic Fibrosis | Completed | 2018-10-02 | 2020-08-07 | ClinicalTrials.gov |
| NCT03655678 | A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-… | Phase2 | Beta-Thalassemia | Completed | 2018-09-14 | 2025-11-13 | ClinicalTrials.gov |
| NCT03601637 | Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to L… | Phase3 | Cystic Fibrosis | Completed | 2018-09-07 | 2021-10-29 | ClinicalTrials.gov |
| NCT03625466 | A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in… | Phase2 | Cystic Fibrosis | Completed | 2018-08-10 | 2021-10-07 | ClinicalTrials.gov |
| NCT03525548 | A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/… | Phase3 | Cystic Fibrosis | Completed | 2018-08-03 | 2018-12-28 | ClinicalTrials.gov |
| NCT03633526 | Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of … | Phase3 | Cystic Fibrosis | Terminated | 2018-08-03 | 2019-01-18 | ClinicalTrials.gov |
| NCT03447262 | A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Ther… | Phase3 | Cystic Fibrosis | Terminated | 2018-07-13 | 2020-09-09 | ClinicalTrials.gov |
| NCT03525444 | A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis … | Phase3 | Cystic Fibrosis | Completed | 2018-06-15 | 2019-04-24 | ClinicalTrials.gov |
| NCT03559062 | A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 1… | Phase3 | Cystic Fibrosis | Completed | 2018-05-17 | 2018-12-21 | ClinicalTrials.gov |
| NCT03460990 | A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/… | Phase3 | Cystic Fibrosis | Completed | 2018-05-01 | 2018-10-08 | ClinicalTrials.gov |
| NCT03537651 | A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA… | Phase3 | Cystic Fibrosis | Completed | 2018-04-25 | 2023-09-29 | ClinicalTrials.gov |
| NCT03768089 | Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis | Phase1 | Cystic Fibrosis | Completed | 2018-03-20 | 2019-05-03 | ClinicalTrials.gov |
| NCT03447249 | A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis … | Phase3 | Cystic Fibrosis | Completed | 2018-03-07 | 2019-02-05 | ClinicalTrials.gov |
| NCT03227094 | Simplification of CF-related Diabetes Screening at Home | Na | Cystic Fibrosis | Completed | 2017-11-13 | 2020-04-01 | ClinicalTrials.gov |
| NCT04138589 | Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for … | — | Cystic Fibrosis in Children | Completed | 2017-11-01 | 2022-07-19 | ClinicalTrials.gov |
| NCT03304028 | MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique | Na | Cystic Fibrosis | Terminated | 2017-10-20 | 2020-06-18 | ClinicalTrials.gov |
| NCT03304522 | A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With… | Phase2 | Small Fiber Neuropathy | Completed | 2017-09-20 | 2018-11-08 | ClinicalTrials.gov |
| NCT03277196 | A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants… | Phase3 | Cystic Fibrosis | Completed | 2017-08-16 | 2023-10-02 | ClinicalTrials.gov |
| NCT03224351 | A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Sub… | Phase2 | Cystic Fibrosis | Completed | 2017-08-08 | 2018-02-28 | ClinicalTrials.gov |
| NCT03068312 | A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who … | Phase3 | Cystic Fibrosis | Completed | 2017-07-18 | 2018-12-18 | ClinicalTrials.gov |
| NCT03163511 | A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Sub… | Phase1 | Type 1 Diabetes Mellitus With Hypoglycemia | Completed | 2017-07-06 | 2023-10-19 | ClinicalTrials.gov |
| NCT03206749 | A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain F… | Phase2 | Acute Pain | Completed | 2017-06-29 | 2017-12-08 | ClinicalTrials.gov |
| NCT03150719 | A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (… | Phase3 | Cystic Fibrosis | Completed | 2017-05-24 | 2018-08-09 | ClinicalTrials.gov |
| NCT03125395 | A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Ol… | Phase3 | Cystic Fibrosis | Completed | 2017-05-12 | 2019-07-17 | ClinicalTrials.gov |
| NCT03085485 | The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor | Phase2 | Chronic Obstructive Pulmonary Disease | Completed | 2017-03-16 | 2022-09-30 | ClinicalTrials.gov |
| NCT03061331 | Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E … | Phase2 | Cystic Fibrosis | Completed | 2017-01-31 | 2017-10-04 | ClinicalTrials.gov |
| NCT03227471 | A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis | Phase1 | Cystic Fibrosis | Completed | 2017-01-23 | 2018-03-27 | ClinicalTrials.gov |
| NCT02971839 | Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fi… | Phase2 | Cystic Fibrosis | Terminated | 2016-12-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02953314 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Iv… | Phase3 | Cystic Fibrosis | Completed | 2016-11-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT02934698 | An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and … | Phase3 | Cystic Fibrosis | Completed | 2016-11-01 | 2018-05-01 | ClinicalTrials.gov |
| NCT02951195 | A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cyst… | Phase2 | Cystic Fibrosis | Completed | 2016-11-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT03029455 | A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects a… | Phase1 | Cystic Fibrosis | Completed | 2016-11-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02951182 | A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Sub… | Phase2 | Cystic Fibrosis | Completed | 2016-10-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02730208 | A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest… | Phase2 | Cystic Fibrosis | Completed | 2016-09-01 | 2018-07-01 | ClinicalTrials.gov |
| NCT02875366 | A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance … | Phase4 | Cystic Fibrosis | Completed | 2016-09-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02871778 | Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia | Phase2 | Primary Ciliary Dyskinesia | Completed | 2016-08-01 | 2018-11-20 | ClinicalTrials.gov |
| NCT03486236 | A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Te… | Phase1 | Cystic Fibrosis | Completed | 2016-07-20 | 2016-09-14 | ClinicalTrials.gov |
| NCT02669849 | Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Trauma… | Phase2 | Cervical Spinal Cord Injury | Terminated | 2016-07-01 | 2018-11-01 | ClinicalTrials.gov |
| NCT02725567 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivaca… | Phase3 | Cystic Fibrosis | Completed | 2016-06-02 | 2022-06-28 | ClinicalTrials.gov |
| NCT02823470 | A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Luma… | Phase4 | Cystic Fibrosis | Terminated | 2016-06-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02742519 | A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fi… | Phase3 | Cystic Fibrosis | Terminated | 2016-05-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02797132 | Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Thr… | Phase3 | Cystic Fibrosis | Completed | 2016-05-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT02508207 | A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmon… | Phase2 | Cystic Fibrosis | Completed | 2016-02-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02709109 | A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic F… | Phase2 | Cystic Fibrosis | Completed | 2016-02-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT02660424 | A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of… | Phase2 | Osteoarthritis | Completed | 2015-12-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02722057 | A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patien… | — | Cystic Fibrosis | Completed | 2015-12-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT02565914 | A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 … | Phase3 | Cystic Fibrosis | Completed | 2015-08-01 | 2022-12-05 | ClinicalTrials.gov |
| NCT02544451 | Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With … | Phase3 | Cystic Fibrosis | Completed | 2015-08-01 | 2020-04-01 | ClinicalTrials.gov |
| NCT02516410 | A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivaca… | Phase3 | Cystic Fibrosis | Completed | 2015-08-01 | 2016-06-07 | ClinicalTrials.gov |
| NCT02514473 | A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With I… | Phase3 | Cystic Fibrosis | Completed | 2015-07-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02412111 | A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) i… | Phase3 | Cystic Fibrosis | Completed | 2015-06-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT02445053 | Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gatin… | — | Cystic Fibrosis | Completed | 2015-04-01 | 2020-10-01 | ClinicalTrials.gov |
| NCT02343445 | Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibro… | Phase2 | Cystic Fibrosis | Completed | 2015-04-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02392234 | A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in … | Phase3 | Cystic Fibrosis | Completed | 2015-03-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02390219 | Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Y… | Phase3 | Cystic Fibrosis | Completed | 2015-03-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02347657 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluat… | Phase3 | Cystic Fibrosis | Completed | 2015-01-01 | 2017-01-20 | ClinicalTrials.gov |
| NCT03338595 | Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients … | — | Cystic Fibrosis | Completed | 2014-05-01 | 2020-10-01 | ClinicalTrials.gov |
| NCT02141464 | Energy Balance and Weight Gain With Ivacaftor Treatment | — | Cystic Fibrosis | Completed | 2014-03-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02070744 | Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor i… | Phase2 | Cystic Fibrosis | Completed | 2014-03-01 | 2016-05-27 | ClinicalTrials.gov |
| NCT02015507 | An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects o… | Phase1 | Cystic Fibrosis | Completed | 2014-01-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01946412 | Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Tr… | Phase3 | Cystic Fibrosis | Completed | 2013-12-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01994486 | Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Gen… | Phase2 | Hepatitis C, Chronic | Completed | 2013-12-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01931839 | A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subject… | Phase3 | Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation | Completed | 2013-10-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01890772 | Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 | Phase2 | Hepatitis C | Withdrawn | 2013-08-01 | — | ClinicalTrials.gov |
| NCT01897233 | Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Year… | Phase3 | Cystic Fibrosis | Completed | 2013-07-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01899105 | A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination Wit… | Phase1 | Cystic Fibrosis | Completed | 2013-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01886209 | Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolon… | Phase1 | Drug Interactions | Completed | 2013-06-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01910415 | Phase 1, QT/QTC Interval Study in Healthy Subjects | Phase1 | Cystic Fibrosis | Completed | 2013-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01888393 | Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hep… | Phase1 | Hepatic Impairment | Completed | 2013-06-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01842451 | A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmac… | Phase2 | Chronic Hepatitis C | Completed | 2013-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01807923 | A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects… | Phase3 | Cystic Fibrosis, Homozygous for the F508del CFTR Mutation | Completed | 2013-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01863238 | An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age … | — | Cystic Fibrosis | Completed | 2013-05-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01821963 | Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcino… | Phase3 | Infection | Terminated | 2013-04-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01807949 | A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects… | Phase3 | Cystic Fibrosis, Homozygous for the F508del CFTR Mutation | Completed | 2013-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01830985 | A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficac… | Phase2 | Rheumatoid Arthritis | Completed | 2013-04-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01790100 | A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Eff… | Phase2 | Chronic Hepatitis C | Completed | 2013-02-28 | 2014-06-30 | ClinicalTrials.gov |
| NCT01707290 | Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CF… | Phase3 | Cystic Fibrosis | Completed | 2013-02-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01701063 | An Open-Label Study of the Effect of Telaprevir in Combination With Peginterfer… | Phase1 | Hepatitis C | Terminated | 2013-01-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01768663 | A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itracona… | Phase1 | Cystic Fibrosis | Completed | 2013-01-01 | — | ClinicalTrials.gov |
| NCT01754935 | A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects… | Phase2 | Rheumatoid Arthritis | Completed | 2013-01-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01705145 | Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a … | Phase3 | Cystic Fibrosis | Completed | 2013-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01704521 | Viral Kinetics in HCV Clearance in Subjects With Hemophilia | Phase1 | Chronic Hepatitis C | Completed | 2012-12-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01726946 | A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in… | Phase2 | Chronic Hepatitis C | Completed | 2012-11-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01685801 | Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With C… | Phase2 | Cystic Fibrosis | Completed | 2012-09-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01614457 | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF … | Phase3 | Cystic Fibrosis | Completed | 2012-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01614470 | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D C… | Phase3 | Cystic Fibrosis | Completed | 2012-07-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01581138 | VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects … | Phase2 | Chronic Hepatitis C Virus | Completed | 2012-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01590459 | 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in S… | Phase2 | Rheumatoid Arthritis | Completed | 2012-04-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01561807 | A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live In… | Phase2 | Influenza Virus | Completed | 2012-03-01 | — | ClinicalTrials.gov |
| NCT01531673 | Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous … | Phase2 | Cystic Fibrosis | Completed | 2012-02-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01467505 | An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin a… | Phase2 | Hepatitis C | Terminated | 2012-02-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01516918 | A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telap… | Phase2 | Chronic Hepatitis C Virus | Completed | 2012-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01511432 | A Study to Assess the Relative Bioavailability Three New Formulations of Telapr… | Phase1 | Chronic Hepatitis C | Completed | 2012-01-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01467492 | Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African Ame… | Phase4 | Hepatitis C | Terminated | 2012-01-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01554085 | First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunte… | Phase1 | Hepatitis C, Chronic | Terminated | 2011-12-31 | 2012-09-30 | ClinicalTrials.gov |
| NCT01590407 | First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunte… | Phase1 | Hepatitis C, Chronic | Completed | 2011-12-31 | 2013-02-28 | ClinicalTrials.gov |
| NCT01501383 | A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatmen… | Phase2 | Epilepsy | Terminated | 2011-12-01 | — | ClinicalTrials.gov |
| NCT01467479 | A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are… | Phase3 | Hepatitis C | Terminated | 2011-12-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01459913 | Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribaviri… | Phase3 | Hepatitis C, Chronic | Terminated | 2011-11-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01262352 | Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cysti… | Phase2 | Cystic Fibrosis | Completed | 2011-01-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01275599 | Drug-Drug Interaction Study Between Telaprevir and Buprenorphine | Phase1 | Hepatitis C | Completed | 2011-01-01 | — | ClinicalTrials.gov |
| NCT01241760 | VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Tela… | Phase3 | Genotype 1 Chronic Hepatitis C | Completed | 2010-12-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01253551 | VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir | Phase1 | Hepatitis C | Completed | 2010-12-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01225211 | Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Pa… | Phase2 | Cystic Fibrosis | Completed | 2010-10-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01216046 | Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects | Phase1 | Cystic Fibrosis | Completed | 2010-10-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01161537 | Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Ima… | Phase2 | Cystic Fibrosis | Completed | 2010-10-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01208285 | Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Hea… | Phase1 | In Development for Cystic Fibrosis | Completed | 2010-09-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01080222 | A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Trea… | Phase2 | Chronic Hepatitis C Virus Infection | Terminated | 2010-08-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01117012 | Rollover Study of VX-770 in Cystic Fibrosis Subjects | Phase3 | Cystic Fibrosis | Completed | 2010-07-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01153542 | Study of VX-770 on Desipramine | Phase1 | In Development for Cystic Fibrosis | Completed | 2010-06-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT01144936 | Study of VX-985 in Subjects With Chronic Hepatitis C | Phase1 | Chronic Hepatitis C | Completed | 2010-06-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT01054573 | VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the … | Phase3 | Hepatitis C, Chronic | Completed | 2010-04-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01060566 | Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on… | Phase1 | Cystic Fibrosis | Completed | 2010-02-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01052194 | A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthrit… | Phase2 | Rheumatoid Arthritis | Completed | 2010-02-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01038167 | A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosp… | Phase1 | Hepatitis C | Completed | 2010-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01048255 | Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy | Phase2 | Partial Epilepsy | Completed | 2010-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01018368 | Study of VX-770 and Rifampin in Healthy Male Subjects | Phase1 | Cystic Fibrosis | Completed | 2009-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00983853 | Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and… | Phase2 | Hepatitis C | Completed | 2009-10-01 | — | ClinicalTrials.gov |
| NCT00973388 | VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the … | Phase1 | Hepatitis C | Completed | 2009-10-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00966602 | Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects | Phase1 | Cystic Fibrosis | Completed | 2009-09-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00953706 | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygo… | Phase2 | Cystic Fibrosis | Terminated | 2009-09-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00909727 | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551… | Phase3 | Cystic Fibrosis | Completed | 2009-08-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00958152 | Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects | Phase1 | Hepatitis C | Completed | 2009-08-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00933283 | A Study to Investigate the Potential Interaction Between Telaprevir and Methado… | Phase1 | Healthy Participants | Completed | 2009-07-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00909532 | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the… | Phase3 | Cystic Fibrosis | Completed | 2009-06-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00916474 | Virology Follow up Study in Subjects Previously Treated With Telaprevir | — | Hepatitis C | Completed | 2009-06-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00892697 | Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV) | Phase2 | Hepatitis C | Completed | 2009-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00911963 | Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chroni… | Phase1 | Hepatitis C | Completed | 2009-04-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00923728 | A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage So… | Na | Refractory Solid Tumors | Withdrawn | 2009-04-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00865904 | Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation | Phase2 | Cystic Fibrosis | Completed | 2009-03-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00781274 | Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic H… | Phase3 | Hepatitis C | Completed | 2008-12-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00780910 | Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients… | Phase3 | Chronic Hepatitis C | Completed | 2008-11-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00780416 | Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Tr… | Phase3 | Hepatitis C | Completed | 2008-11-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00789126 | Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects | Phase1 | Healthy | Completed | 2008-10-01 | — | ClinicalTrials.gov |
| NCT00758043 | A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Na… | Phase3 | Hepatitis C | Completed | 2008-10-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00630058 | A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C | Phase1 | Hepatitis C | Completed | 2008-04-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00627926 | A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Trea… | Phase3 | Hepatitis C | Completed | 2008-03-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00621296 | Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C | Phase2 | Hepatitis C | Completed | 2008-01-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00591214 | Safety and PK Study of MP-424 to Treat Chronic Hepatitis C | Phase1 | Chronic Hepatitis C | Completed | 2007-12-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00623649 | Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916… | Phase1 | HCV Infection | Completed | 2007-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00535847 | A Rollover Study for Subjects Participating in the Control Arm of Study VX06-95… | Phase2 | Hepatitis C | Completed | 2007-10-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00509210 | Study of Telaprevir in Subjects With Hepatic Impairment | Phase1 | Hepatic Insufficiency | Completed | 2007-09-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00493441 | AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer | Phase2 | Pancreatic Cancer | Terminated | 2007-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00457821 | Safety Study of Ivacaftor in Subjects With Cystic Fibrosis | Phase2 | Cystic Fibrosis | Completed | 2007-05-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00420784 | A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) | Phase2 | Hepatitis C | Completed | 2007-02-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00395577 | A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inh… | Phase2 | Rheumatoid Arthritis | Completed | 2006-11-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00389298 | A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection. | Phase1 | Hepatitis C, Chronic | Completed | 2006-10-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00372385 | Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C | Phase2 | Chronic Hepatitis C | Completed | 2006-08-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00336479 | Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C | Phase2 | Chronic Hepatitis C | Completed | 2006-06-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00273936 | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | Phase1 | Acute Leukemia | Completed | 2006-01-01 | — | ClinicalTrials.gov |
| NCT00262483 | Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C | Phase2 | Hepatitis C | Completed | 2005-12-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00251199 | VX-950 and Peginterferon for Hepatitis C | Phase1 | Hepatitis C | Completed | 2005-10-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00205478 | Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38… | Phase2 | Rheumatoid Arthritis | Completed | 2005-06-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00500812 | A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cerv… | Phase1 | Spinal Cord Injury | Completed | 2005-02-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00205465 | Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 | Phase2 | Psoriasis | Completed | 2004-12-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00088504 | Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis… | Phase2 | Hepatitis C | Completed | 2004-07-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00003847 | VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurre… | Phase2 | Lung Cancer | Terminated | 1998-12-01 | — | ClinicalTrials.gov |
Total clinical trials: 286
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Efavirenz | Other | Phase PHASE1 | Pain | COMPLETED | NCT07570069 |
| Suzetrigine | Other | Phase PHASE1 | Pain | COMPLETED | NCT07570069 |
| Placebo | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| Suzetrigine | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| VX-407 | Other | Phase PHASE2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | ACTIVE_NOT_RECRUITING | NCT07161037 |
| IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05331183 |
| ELX/TEZ/IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05331183 |
| CTX001 | Other | Phase PHASE3 | Beta-Thalassemia | ENROLLING_BY_INVITATION | NCT04208529 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT06154447 |
| VX-670 | Other | Phase PHASE2 | Myotonic Dystrophy Type 1 (DM1) | ENROLLING_BY_INVITATION | NCT06926621 |
| Placebo | Other | Phase PHASE2 | Proteinuric Kidney Disease | RECRUITING | NCT05312879 |
| VX-147 | Other | Phase PHASE2 | Proteinuric Kidney Disease | RECRUITING | NCT05312879 |
| Tacrolimus | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07204275 |
| Povetacicept | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07204275 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| VX-407 | Other | Phase PHASE2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | ACTIVE_NOT_RECRUITING | NCT07161037 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05331183 |
| ELX/TEZ/IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05331183 |
| VX-121/TEZ/D-IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05444257 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Tacrolimus | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07204275 |
| Povetacicept | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07204275 |
| TEZ | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| D-IVA | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| CTX001 | Other | Phase PHASE3 | Beta-Thalassemia | ACTIVE_NOT_RECRUITING | NCT05356195 |
| CTX001 | Other | Phase PHASE3 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT05329649 |
| VX-670 | Other | Phase PHASE2 | Myotonic Dystrophy Type 1 (DM1) | ENROLLING_BY_INVITATION | NCT06926621 |
| IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05331183 |
| ELX/TEZ/IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05331183 |
| VX-880 | Other | Phase PHASE3 | Diabetes Mellitus, Type 1 | RECRUITING | NCT04786262 |
| Efavirenz | Other | Phase PHASE1 | Pain | ACTIVE_NOT_RECRUITING | NCT07570069 |
| Suzetrigine | Other | Phase PHASE1 | Pain | ACTIVE_NOT_RECRUITING | NCT07570069 |
| Tacrolimus | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07204275 |
| Povetacicept | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07204275 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Placebo | Other | Phase PHASE2 | Proteinuric Kidney Disease | RECRUITING | NCT05312879 |
| VX-147 | Other | Phase PHASE2 | Proteinuric Kidney Disease | RECRUITING | NCT05312879 |
| Suzetrigine | Other | Phase PHASE3 | Opioid Consumption, Postoperative | NOT_YET_RECRUITING | NCT07654296 |
| multimodal analgesia regimen without suzetrigine | Other | Phase PHASE3 | Opioid Consumption, Postoperative | NOT_YET_RECRUITING | NCT07654296 |
| Placebo (matched to Pregabalin) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT06628908 |
| Pregabalin | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT06628908 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT06628908 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT06628908 |
| VX-407 | Other | Phase PHASE2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | RECRUITING | NCT07161037 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Placebo | Other | Phase PHASE1 | Myotonic Dystrophy Type 1 (DM1) | RECRUITING | NCT06185764 |
| VX-670 | Other | Phase PHASE1 | Myotonic Dystrophy Type 1 (DM1) | RECRUITING | NCT06185764 |
| Bupropion | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | RECRUITING | NCT07584434 |
| Midazolam | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | RECRUITING | NCT07584434 |
| Placebo | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | RECRUITING | NCT07584434 |
| VX-433 | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | RECRUITING | NCT07584434 |
| IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06460506 |
| ELX/TEZ/IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06460506 |
| Tacrolimus | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07204275 |
| Povetacicept | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07204275 |
| VX-264 | Other | Phase PHASE1 | Type 1 Diabetes | ACTIVE_NOT_RECRUITING | NCT05791201 |
| Suzetrigine | Other | Phase PHASE4 | Knee Arthritis | NOT_YET_RECRUITING | NCT07624526 |
| Placebo | Other | Phase PHASE2 | Proteinuric Kidney Disease | RECRUITING | NCT05312879 |
| VX-147 | Other | Phase PHASE2 | Proteinuric Kidney Disease | RECRUITING | NCT05312879 |
| Efavirenz | Other | Phase PHASE1 | Pain | RECRUITING | NCT07570069 |
| Suzetrigine | Other | Phase PHASE1 | Pain | RECRUITING | NCT07570069 |
| Placebo (matched to VX-993) | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT06619860 |
| Placebo (matched to pregabalin) | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT06619860 |
| Pregabalin | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT06619860 |
| VX-993 | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT06619860 |
| VX-670 | Other | Phase PHASE2 | Myotonic Dystrophy Type 1 (DM1) | ENROLLING_BY_INVITATION | NCT06926621 |
| IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05331183 |
| ELX/TEZ/IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05331183 |
| VX-121/TEZ/D-IVA | Other | Phase PHASE3 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05422222 |
| Placebo (matched to HB/APAP) | Other | Phase PHASE2 | Acute Pain | COMPLETED | NCT06619847 |
| Placebo (matched to VX-993) | Other | Phase PHASE2 | Acute Pain | COMPLETED | NCT06619847 |
| HB/APAP | Other | Phase PHASE2 | Acute Pain | COMPLETED | NCT06619847 |
| VX-993 | Other | Phase PHASE2 | Acute Pain | COMPLETED | NCT06619847 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Deutivacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-118 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Tezacaftor | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Midazolam | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Itraconazole | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| VX-828 | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT06154447 |
| IVA | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05668741 |
| VX-522 mRNA therapy | Drug | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05668741 |
| IVA | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05668741 |
| VX-522 mRNA therapy | Drug | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05668741 |
| IVA | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05668741 |
| VX-522 mRNA therapy | Drug | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05668741 |
| IVA | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05668741 |
| VX-522 mRNA therapy | Drug | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05668741 |
| IVA | Other | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05668741 |
| VX-522 mRNA therapy | Drug | Phase PHASE1 | Cystic Fibrosis | ACTIVE_NOT_RECRUITING | NCT05668741 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo (matched to SUZ) | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | RECRUITING | NCT07231419 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Suzetrigine | Other | Phase PHASE3 | Diabetic Peripheral Neuropathic Pain | ACTIVE_NOT_RECRUITING | NCT06696443 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| VX-581 | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT07283770 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Povetacicept | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | RECRUITING | NCT07501702 |
| Suzetrigine | Other | Phase PHASE1 | Pain | RECRUITING | NCT07378865 |
| VX-407 | Other | Phase PHASE2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | RECRUITING | NCT07161037 |
| Placebo | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| Suzetrigine | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| Bupropion | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Midazolam | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Placebo | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| VX-433 | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Suzetrigine | Other | Phase PHASE1 | Pain | RECRUITING | NCT07378865 |
| VX-407 | Other | Phase PHASE2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | RECRUITING | NCT07161037 |
| Placebo | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| Suzetrigine | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| Bupropion | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Midazolam | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Placebo | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| VX-433 | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| VX-407 | Other | Phase PHASE2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | RECRUITING | NCT07161037 |
| Suzetrigine | Other | Phase PHASE1 | Pain | RECRUITING | NCT07378865 |
| Bupropion | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Midazolam | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Placebo | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| VX-433 | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Placebo | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| Suzetrigine | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| VX-407 | Other | Phase PHASE2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | RECRUITING | NCT07161037 |
| Suzetrigine | Other | Phase PHASE1 | Pain | RECRUITING | NCT07378865 |
| Bupropion | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Midazolam | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Placebo | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| VX-433 | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Placebo | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| Suzetrigine | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| VX-407 | Other | Phase PHASE2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | RECRUITING | NCT07161037 |
| Suzetrigine | Other | Phase PHASE1 | Pain | RECRUITING | NCT07378865 |
| Bupropion | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Midazolam | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Placebo | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| VX-433 | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Placebo | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| Suzetrigine | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| VX-407 | Other | Phase PHASE2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | RECRUITING | NCT07161037 |
| Suzetrigine | Other | Phase PHASE1 | Pain | RECRUITING | NCT07378865 |
| Bupropion | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Midazolam | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Placebo | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| VX-433 | Other | Phase PHASE1 | Narcolepsy Type 1 (NT1) | NOT_YET_RECRUITING | NCT07584434 |
| Placebo | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
| Suzetrigine | Other | Phase PHASE4 | Pain | RECRUITING | NCT07538570 |
Total products: 324